CERo Therapeutics Holdings ( (CERO) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the company’s ongoing efforts to finalize the valuation and accounting treatment of marketable securities received as part of a securities purchase agreement. The company expects to file the report within five calendar days following the prescribed due date. Preliminary financial results indicate a significant increase in net loss, from $2.4 million in the previous year to $18.5 million for the quarter ended June 30, 2025. This increase is attributed to several factors, including stock-based inducement expenses and unrealized losses on equity securities. The company is committed to resolving these issues and maintaining compliance, as indicated by the signature of CFO Andrew Kucharchuk on the notification.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
Average Trading Volume: 1,125,027
Technical Sentiment Signal: Sell
Current Market Cap: $9.69M
For an in-depth examination of CERO stock, go to TipRanks’ Overview page.